Format

Send to

Choose Destination
Mol Oncol. 2012 Apr;6(2):260-6. doi: 10.1016/j.molonc.2012.02.006. Epub 2012 Mar 6.

Paying for personalized care: cancer biomarkers and comparative effectiveness.

Author information

1
Department of Pharmacy, University of Washington, Seattle, WA 98195-7630, USA.

Abstract

Genomic-based diagnostics can play a key role in creating a more efficient healthcare system by directing patients toward beneficial therapies and away from therapies that pose substantial risk or are unlikely to improve outcomes for the patient. We outline how the value provided by diagnostics is closely linked to a range of factors including magnitude of health outcome improvement, avoiding adverse effect, diagnostic parameters, process of care, resource utilization, and costs. Comparative effectiveness approaches to evidence generation, including health outcome measurements, quality of life, economic analyses, decision modeling, and pragmatic clinical trials, can be used to provide stakeholders with a range of information to inform treatment, guidelines, coverage, and reimbursement decisions. Evidence of comparative effectiveness can also help support value-based reimbursement of cancer biomarkers and treatment strategies as means of paying for personalized medicine.

PMID:
22429896
PMCID:
PMC3593045
DOI:
10.1016/j.molonc.2012.02.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center